Deal frequency in life science gives hope for recovery

The beginning of 2023 have seen big pharma open their wallets – at least compared to last year. The deal volume already exceeds that of 2022. Analysts believe this is the start of a surge of deals where pharmaceutical giants aim to secure their portfolios with next-generation blockbuster drugs.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/04/deal-frequency-in-life-science-gives-hope-for-recovery/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se